Medtronic shareholders face up to capital gains tax from Covidien merger

Corporate tax inversions, including Medtronic's ($MDT) planned shift to Ireland following its purchase of Covidien ($COV), are causing a backlash among some shareholders stuck with a big tax bill becaues of capital gains taxes associated with the deal. Anthony Ogorek, founder and operating manager of Ogorek Wealth Management, talked about the predicament of one client and former Medtronic employee explaining the inversion could cause a "forced sale and reissuance of new shares." Depending on the investor's income, the involuntary conversions could be taxed a heavy 32.8%, before even accounting for state taxes. Read More

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.